Park Medi World IPO Date, Review, Price and Key Information

Park Medi World Limited IPO is fully book build issue and total IPO size is ₹1260 crores. The offering includes a fresh issue worth ₹960 crores and an offer for sale of ₹300 crores.

The dates for the Park Medi World Limited IPO have not been announced yet. The allotment process is expected to be finalized by [.].

The Park Medi World Limited IPO is scheduled to list on BSE, NSE, with a listing date of [.]. The price band for the Park Medi World Limited IPO has not been announced yet.

Registrar for this IPO is Kfin Technologies Limited and lead managers for Park Medi World Limited IPO are Nuvama Wealth Management Limited, Clsa India Private Limited, Dam Capital Advisors Limited, Intensive Fiscal Services Private Limited.

IPO Schedule

IPO Open Date	-
IPO Close Date	-
IPO Allotment Date	-
Refund Initiation	-
Share credit in Demat	-
Listing Date	-

Key Details

Price Band	TBA
Lot Size	TBA
Face Value	₹2 Per Equity Share
Total Issue Size	₹1,260.00 Crores
Fresh Issue	₹960.00 Crores
OFS Issue	₹300.00 Crores
Issue Type	Fresh Issue and Offer for Sale
Listing At	BSE, NSE

Share Reservation

Investor Category	Shares Offered
QIB	50%
Retail	35%
NII/HNI	15%

About Park Medi World Limited Company

Park Medi World Limited (PMWL) is the second largest private hospital chain in North India, operating 13 NABH accredited multi-super specialty hospitals under the ‘Park’ brand. As of September 30, 2024, PMWL has an aggregate bed capacity of 3,000 beds, with 1,600 beds located in Haryana, making it the largest private hospital chain in the state. The hospital network provides over 30 super specialty and specialty services, including internal medicine, neurology, urology, and oncology. PMWL employs a dedicated team of 891 doctors and 1,912 nurses.

PMWL has expanded its bed capacity from 2,250 beds as of March 31, 2022 to 3,000 beds as of September 30, 2024, and has ongoing expansion projects in Ambala, Panchkula, Rohtak, New Delhi and Gorakhpur. PMWL's revenue from operations for the six months ended September 30, 2024, was ₹6,915.06 million with an EBITDA of ₹1,896.20 million. PMWL's commitment to quality and affordable care is reflected in its operational and financial performance, demonstrating its ability to successfully integrate acquired hospitals into its network. PMWL has cultivated a reputation in patient care with a vision to provide ‘wellness for all’.

Park Medi World Limited Financial Details

Period Ended	30 Sep 2024	31 Mar 2024	31 Mar 2023	31 Mar 2022
Assets	2018.74	1912.10	1592.83	1293.23
Revenue	691.51	1231.07	1254.60	1084.38
Profit After Tax	112.89	152.01	228.19	199.38
Net Worth	1048.21	935.51	729.97	543.99
Reserves and Surplus	913.13	805.92	609.68	379.91
Total Borrowing	596.52	632.65	557.24	503.35

₹ In Crore

Key Performance Indicator

Basic EPS (in ₹)	Return on Net Worth (RoNW)	Net Asset Value (NAV)	Debt-Equity Ratio	Return on Equity (ROE)	Return on Capital Employed (ROCE)
3.95	18.81%	21.23	0.73	18.25%	16.07%

Offer Objectives

The Offer comprises a fresh issue of equity shares aggregating up to ₹96 crore and an Offer for Sale (OFS) of equity shares aggregating up to ₹30 crore by the Promoter Selling Shareholder. The company will not receive any proceeds from the OFS.

Objects of the Offer: The company proposes to utilize the net proceeds from the fresh issue towards:

Repayment/prepayment of certain outstanding borrowings availed by the Company and its Subsidiaries.
Funding capital expenditure for the development of a new hospital and expansion of an existing hospital by certain Subsidiaries.
Funding capital expenditure for the purchase of medical equipment by the Company and its certain Subsidiaries.
Unidentified inorganic acquisitions and general corporate purposes.

The gross proceeds from the fresh issue are estimated at ₹96 crore, with offer-related expenses to be borne by the company. Net proceeds will be used as follows: ₹41 crore for repayment/prepayment of borrowings, ₹11 crore for new hospital development and existing hospital expansion, and ₹7.71 crore for medical equipment purchase. A portion is reserved for unidentified inorganic acquisitions and general corporate purposes, not exceeding 35% of gross proceeds. A Pre-IPO placement aggregating up to ₹19.2 crore may be considered, which would reduce the offer size.

The repayment/prepayment of borrowings will help the Company and Subsidiaries in reducing outstanding indebtedness, assist us in maintaining a favorable debt-equity ratio, reduce our interest outflow and enable utilization of some additional amount from our internal accruals for further investment in business growth and expansion. In addition, we believe that our debt -equity ratio may also improve, which will enable us to raise additional funds/ capital at competitive rates in the future to fund potential business development opportunities and plans to grow and expand our business in the future.